This clinical study is sponsored by Neuren Pharmaceuticals, a biopharmaceutical company headquartered in Melbourne, Australia focusing on the development of therapies for neurodevelopmental and neurodegenerative disorders. Current trials target neurodevelopmental disorders such as Angelman, Phelan-McDermid and Pitt Hopkins syndromes.

Prior to NNZ-2591, Neuren partnered with Acadia Pharmaceuticals to develop a treatment for patients with Rett syndrome. After years of hard work, on March 10 2023, Acadia Pharmaceuticals received marketing approval from the U.S. Food and Drug Administration (FDA) for DAYBUE™ (trofinetide) to treat Rett syndrome in adults and pediatric patients 2 years of age and older. 

Please refer to our corporate website if you’d like more information:

For more information on these current studies, please visit

For more information on Neuren Pharmaceuticals, visit

Further information provided by other websites and organisations for additional resources about Prader-Willi syndrome can be found below.

Foundation for Prader-Willi Research (FPWR)

The Foundation for Prader-Willi Research was established with one aim in mind: to eliminate the challenges of Prader-Willi syndrome through the advancement of research and therapeutic development.

More information can be found via the

PWSA | USA (Prader-Willi Syndrome Association | USA)

PWSA | USA has a mission to enhance the quality of life of and empower those affected by Prader-Willi syndrome.

More information can be found via the is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world, according to their website. The service is supported by the National Institutes of Health.

You can find our entry at: